Neuro Startup BrainAurora Completes HK IPO

（the article has been updated to make the text concise and cohesive)

No.1 IPO in 2025

BrainAurora has made history as the first neurotech company from Mainland China to go public in Hong Kong. It also marks the first initial public offering (IPO) of 2025.

Based in Shaoxing, Zhejiang Province, the company raised HKD 538 million through its IPO, with plans to allocate these funds toward research and development (R&D) for cognitive centers across China. The company is focused on addressing dementia and other neurodegenerative conditions.

BrainAurora combines neuroscience with artificial intelligence to develop products aimed at diagnosing and treating cognitive disorders associated with vascular diseases, neurodegenerative conditions, mental illnesses, and developmental defects. Its flagship product, "66nao," supports clinical assessment, treatment, and outcome management. This product is already in use at over 120 cognitive centers across China.

China’s rapidly aging population has increased demand for services aimed at cognitive training and memory retention, particularly among senior citizens.

The rise of neuro startups in China has been fueled by an increasing focus on mental health issues among youth and a growing need for dementia care among the elderly.

According to SCMP, BrainAurora plans to expand and scale its services to more facilities across China.